Find out top 10 company by 2026 sales. Propelled by new rollouts in oncology, multiple sclerosis and hemophilia, Roche is set to lead all Big Pharma companies in 2026 sales, according to consensus forecasts from EvaluatePharma. With nearly $62 billion in expected drug sales that year, analysts believe the drugmaker will easily beat the second-place company, Pfizer, with its expected $56.1 billion.
Behind Pfizer, Johnson & Johnson, Novartis, AbbVie and Merck & Co. are all set to pull in more than $50 billion in 2026 drug sales, the analysts predict. Besides the launches already in the works and pipeline candidates advancing when 2020 began, they’ve all joined the hunt for COVID-19 drugs and vaccines.
Here is the chart of 10 Global Company by actual 2019 and by projected 2026.
|Ranking||By projected 2026 drug sales||By actual 2019 drug sales|
|3||Johnson & Johnson||Novartis|
|4||Novartis||Johnson & Johnson|
|5||AbbVie||Merck & Co.|
|6||Merck & Co.||Sanofi|
|9||Bristol Myers Squibb||Takeda|
|10||AstraZeneca||Bristol Myers Squibb|